- Home
- CSTL vs EVAC Comparison
CSTL vs EVAC Comparison
Compare CSTL & EVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSTL | EVAC |
|---|---|---|
| Founded | 2007 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 592.7M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CSTL | EVAC |
|---|---|---|
| Price | $34.49 | $10.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $45.50 | N/A |
| AVG Volume (30 Days) | ★ 275.5K | 127.4K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $2.42 | N/A |
| Revenue Next Year | $12.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $17.72 | $9.90 |
| 52 Week High | $44.28 | $10.33 |
Technical Indicators
Market Signals| Indicator | CSTL | EVAC |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 57.81 |
| Support Level | $22.88 | $10.25 |
| Resistance Level | $42.03 | N/A |
| Average True Range (ATR) | 1.44 | 0.01 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 57.86 | 40.00 |
Price Performance
Historical ComparisonAbout CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
About EVAC EQV Ventures Acquisition Corp. II Class A Ordinary Shares
EQV Ventures Acquisition Corp II is a blank check company.